CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Protagonist Therapeutics, Inc. - PTGX CFD

35.83
0.42%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 35.67
Open 35.84
1-Year Change 73.56%
Day's Range 35.36 - 35.91
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 18, 2024 35.67 0.07 0.20% 35.60 36.35 35.05
Jul 17, 2024 35.88 -0.84 -2.29% 36.72 37.72 35.87
Jul 16, 2024 37.76 1.05 2.86% 36.71 37.95 36.71
Jul 15, 2024 36.65 0.43 1.19% 36.22 37.07 36.22
Jul 12, 2024 36.07 0.25 0.70% 35.82 36.78 35.59
Jul 11, 2024 35.71 0.14 0.39% 35.57 36.25 34.90
Jul 10, 2024 34.74 0.94 2.78% 33.80 34.92 33.80
Jul 9, 2024 34.43 -0.25 -0.72% 34.68 35.08 34.26
Jul 8, 2024 34.65 0.52 1.52% 34.13 35.46 34.01
Jul 5, 2024 33.63 -0.47 -1.38% 34.10 34.24 33.17
Jul 3, 2024 33.96 -0.49 -1.42% 34.45 34.82 33.96
Jul 2, 2024 34.56 -0.62 -1.76% 35.18 35.77 34.23
Jul 1, 2024 35.16 0.54 1.56% 34.62 35.74 34.61
Jun 28, 2024 34.58 -0.68 -1.93% 35.26 35.26 33.36
Jun 27, 2024 31.82 0.10 0.32% 31.72 32.02 31.25
Jun 26, 2024 31.72 0.28 0.89% 31.44 32.02 30.60
Jun 25, 2024 31.66 -0.14 -0.44% 31.80 32.49 31.36
Jun 24, 2024 31.97 -0.36 -1.11% 32.33 32.74 31.83
Jun 21, 2024 32.20 0.73 2.32% 31.47 33.32 30.96
Jun 20, 2024 31.39 -0.58 -1.81% 31.97 32.52 31.18

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Protagonist Therapeutics, Inc. Company profile

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).

Industry: Biotechnology & Medical Research (NEC)

7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US

People also watch

ETH/USD

3,453.76 Price
+1.090% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

19,539.50 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.57 Price
-0.930% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,406.09 Price
-1.600% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading